US 2026/0092056 A1Published application

Melanocortin-4 receptor agonists

AssigneeLG Chem, Ltd.

InventorsSeung Wan Kang, Hee Dong Park, Hee Dong Park, Su Jin Yeo, Hyun Seo Park, Ji Ho Hong, Hye Won Ahn, Eun Sil Choi

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.

Claims19

Dependent claims

A compound of the following Formula 1, or a pharmaceutically acceptable salt or isomer thereof:

wherein R1 is C2-C5 alkyl.

Dependencies are inferred from the claim text.

Facts

Application: 19/410,552Filed 5 Dec 2025
Priority: KR 10-2019-01416497 Nov 2019
Published: 2 Apr 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
C07D 413/14
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms:…
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
A61P 15/10
Drugs for genital or sexual disorders ; Contraceptives: for impotence

Family

Application17/619,893Continuation
Application19/410,552Continuation
US 12,516,047 B2Related patent
US 2022/0289731 A1Published application
US 2026/0092056 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key